Literature DB >> 9158270

The cult of the double-blind placebo-controlled trial.

S J Ellis1, R F Adams.   

Abstract

The double-blind, placebo-controlled trial is held as the gold standard in medical knowledge, but this tool of investigation has its weaknesses. These include ethical limitations on the types of comparison that can be undertaken, the central conflict between best practice for an individual and trial protocols, problems of applicability to the general population and applicability of work done on one population to another, type II errors, publication bias, misuse and limitation of statistics, fraud, maintenance of blinding, asking the wrong question, and a simplistic, reductionist view of clinical management. The concentration on the randomised, controlled trial devalues information from other sources, such as natural history studies, clinical experience and case reports. The randomised, controlled trial is an important source of information and as physicians we should welcome more well-crafted trials, but they are not the only source of information.

Entities:  

Mesh:

Year:  1997        PMID: 9158270

Source DB:  PubMed          Journal:  Br J Clin Pract        ISSN: 0007-0947


  2 in total

1.  Some unanswered questions about NICE.

Authors:  S J Ellis
Journal:  J R Soc Med       Date:  1999-10       Impact factor: 5.344

2.  Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study.

Authors:  D Aletaha; T Stamm; T Kapral; G Eberl; J Grisar; K P Machold; J S Smolen
Journal:  Ann Rheum Dis       Date:  2003-10       Impact factor: 19.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.